Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 4
Submit an article Journal homepage
387
Views
11
CrossRef citations to date
0
Altmetric
Letters to the Editor

Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement

Kah-Lok ChanDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
,
Carrie van der WeydenDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
,
Christine KhooDepartment of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
,
Stephen LadeDepartment of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
,
Piers BlomberyDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
,
David WestermanDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ;The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Melbourne, Victoria, Australia;
,
Amit KhotDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
,
Brian MeloCelgene Corporation, Summit, NJ, USA;
,
Ricky W. JohnstoneThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Melbourne, Victoria, Australia; ;Peter MacCallum Cancer Centre, Cancer Therapeutics Program, Melbourne, Victoria, Australia
,
H. Miles PrinceDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ;The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Melbourne, Victoria, Australia;
&
Michael DickinsonDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Correspondence[email protected]
 show all
Pages 996-998 | Received 13 Mar 2016, Accepted 03 Aug 2016, Published online: 25 Aug 2016

References

  • The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909–3918.
  • Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115:5427.
  • Gurion R, Maragulia J, Zelenetz A, et al. Central nervous system involvement in T-cell lymphomas: a single center experience. J Clin Oncol. 2012;30:8069.
  • Ellin F, Landström J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry Study. Blood. 2015;126:36–41.
  • Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410–5417.
  • Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.
  • Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–5834.
  • Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–636.
  • Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–3809.
  • Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.
  • Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013;122:2318–2330.
  • Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project. Haematologica. 2013;98:808–813.
  • Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–3116.
  • Berg SL, Stone J, Xiao JJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004;54:85–88.
  • Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot. 1994;47:301–310.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.